Derivation Web

source_984c78bb6fe94f7d

by researka:v2 · 2026-06-26 10:16:07.143454+04:00

{"content_hash": "sha256:51c9580273c3269fef740ae3f453f68b6b9dfe53fbb1147ad117a49a40082f3d", "edges": [{"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_1", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_2", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_3", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_4", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_5", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_6", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_7", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_8", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_9", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_10", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_11", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_12", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_13", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_14", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_15", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_16", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_17", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_18", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_19", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_20", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_21", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_22", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_23", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_24", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_25", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_26", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_27", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_28", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_29", "type": "contains_claim"}, {"from": "4a4ef105-6735-457c-a03e-c95da4a8e083", "to": "claim_30", "type": "contains_claim"}], "nodes": [{"id": "4a4ef105-6735-457c-a03e-c95da4a8e083", "title": "Hypothesis-Generating Brief: Mesenchymal stem cells — full paper", "type": "publication"}, {"id": "claim_1", "text": "This paper synthesizes evidence on Mesenchymal stem cells across 16 accepted source papers and 1156 high-confidence extracted claims.", "type": "claim"}, {"id": "claim_2", "text": "The evidence profile contains 2 direct clinical sources, 14 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 30 cross-study disagreements across the evidence base.", "type": "claim"}, {"id": "claim_3", "text": "Positive study-level signals are summarized in the immune and inflammation, safety and comorbidity outcome classes, null signals in the safety and comorbidity, contextual adjacent evidence, safety outcome classes, and negative signals in the contextual adjacent evidence outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "type": "claim"}, {"id": "claim_4", "text": "The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "type": "claim"}, {"id": "claim_5", "text": "For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.", "type": "claim"}, {"id": "claim_6", "text": "Mesenchymal stromal cells (MSCs) — broadly defined as adult stromal cells with multi-lineage differentiation capacity and paracrine immunomodulatory activity — have been proposed as a regenerative cell therapy with mechanism-level plausibility across several aging-relevant pathways. The class includes autologous and allogeneic products derived from bone marrow, adipose tissue, umbilical cord, and placenta, each with distinct expansion and dosing characteristics reflected in the curated evidence base. Human clinical use of MSCs now spans more than two decades of regulatory and experimental work, and MSCs have accumulated a comparatively broad access profile relative to more engineered cell therapies, partly because of their favorable early safety record and partly because of heterologous sourcing. The question of whether this access breadth translates into clinical durability across aging indications, however, remains open. MSCs therefore occupy a unique position: a plausibility-rich, access-friendly candidate class whose clinical evidence base is still being assembled.", "type": "claim"}, {"id": "claim_7", "text": "Several unresolved questions shape how the Mesenchymal evidence base should be interpreted. First, the translation from in vitro and animal immunomodulatory mechanism to human clinical function remains uncertain, with the tension-matrix analysis identifying multiple cross-domain pairings that caution against fusing mechanistic plausibility with clinical-efficacy claims across outcomes. Second, MSCs appear to carry population-specific tradeoffs — dose, route, and source likely interact with baseline frailty and comorbidity, as suggested by the Sartika 2026 dose-and-delivery synthesis — yet these modifiers are rarely tested head-to-head. Third, duration of effect remains poorly characterized: even the longer follow-up cohorts in the curated set stop short of the multi-year horizons that an aging-endpoint argument would require.", "type": "claim"}, {"id": "claim_8", "text": "This synthesis takes a structured-evidence approach: rather than narratively averaging positive and negative findings, it weights studies by directness to the aging question, separates mechanistic signals from clinical-outcome signals, and surfaces the cross-study disagreements identified across outcome classes. The integrating observation is that the MSC anti-aging case is currently incomplete — positive signals in immune-inflammation and safety-comorbidity coexist with negative and null findings in contextual outcomes, and the boundary conditions under which MSCs might meaningfully extend healthspan have not been established. By foregrounding cross-outcome tensions rather than smoothing them, this synthesis aims to make the evidentiary shape of the field legible to clinicians, regulators, and trial designers. The clinical-versus-mechanistic separation adopted throughout the paper is intended to prevent premature claims about longevity extension while still preserving the plausibility signals that justify further, more rigorously designed trials of MSCs in aging populations.", "type": "claim"}, {"id": "claim_9", "text": "The background evidence for Mesenchymal stem cells is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Sadri 2023, Nguyen 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.", "type": "claim"}, {"id": "claim_10", "text": "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "type": "claim"}, {"id": "claim_11", "text": "Across the retained sources, positive signals cluster around the immune and inflammation, safety and comorbidity outcome classes; null signals around the safety and comorbidity, contextual adjacent evidence, safety outcome classes; and negative or adverse signals around the contextual adjacent evidence outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.", "type": "claim"}, {"id": "claim_12", "text": "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "type": "claim"}, {"id": "claim_13", "text": "The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.", "type": "claim"}, {"id": "claim_14", "text": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.", "type": "claim"}, {"id": "claim_15", "text": "Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.", "type": "claim"}, {"id": "claim_16", "text": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "type": "claim"}, {"id": "claim_17", "text": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "type": "claim"}, {"id": "claim_18", "text": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.", "type": "claim"}, {"id": "claim_19", "text": "| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |", "type": "claim"}, {"id": "claim_20", "text": "| Mesenchymal stem cells / Contextual Adjacent Evidence | n=4; claims=197 | significant source statistic in 3/4 sources; receipt-level direction coded null | 4 indirect | limited corpus depth in this outcome class |", "type": "claim"}, {"id": "claim_21", "text": "| Mesenchymal stem cells / Safety | n=1; claims=141 | significant source statistic in 1/1 sources; receipt-level direction coded null | 1 indirect | single-source slice; hypothesis-generating |", "type": "claim"}, {"id": "claim_22", "text": "Contextual Adjacent Evidence: n=4; claims=197; no extracted directional signal in 2/4 sources | directness: 4 indirect; main limitation: no direct clinical anchor.", "type": "claim"}, {"id": "claim_23", "text": "The retained Mesenchymal stem cells corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.", "type": "claim"}, {"id": "claim_24", "text": "The safety and comorbidity evidence packet includes 7 source-level summaries and 401 high-confidence observations. Directional coding within this packet is null=3, positive=1, unclear=3, and directness coding is direct=1, indirect=5, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.", "type": "claim"}, {"id": "claim_25", "text": "Directional coding within this packet is negative=1, null=2, unclear=1, and directness coding is indirect=4.", "type": "claim"}, {"id": "claim_26", "text": "Directional coding within this packet is null=1, positive=1, and directness coding is direct=1, indirect=1.", "type": "claim"}, {"id": "claim_27", "text": "Directional coding within this packet is null=1, and directness coding is review=1.", "type": "claim"}, {"id": "claim_28", "text": "Directional coding within this packet is null=1, and directness coding is indirect=1.", "type": "claim"}, {"id": "claim_29", "text": "Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.", "type": "claim"}, {"id": "claim_30", "text": "Descriptive findings remain separate from interpretation and endpoint-specific boundaries. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13287-023-03359-8", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial", "type": "source", "url": "https://doi.org/10.1186/s13287-023-03359-8", "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1016/j.ebiom.2026.106268", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial", "type": "source", "url": "https://doi.org/10.1016/j.ebiom.2026.106268", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13287-024-03746-9", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease", "type": "source", "url": "https://doi.org/10.1186/s13287-024-03746-9", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13287-025-04577-y", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial", "type": "source", "url": "https://doi.org/10.1186/s13287-025-04577-y", "year": 2025}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1007/s12015-024-10696-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials", "type": "source", "url": "https://doi.org/10.1007/s12015-024-10696-5", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13287-025-04356-9", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Treatment of osteoarthritic knee with high tibial osteotomy and allogeneic human umbilical cord blood–derived mesenchymal stem cells combined with hyaluronate hydrogel composite", "type": "source", "url": "https://doi.org/10.1186/s13287-025-04356-9", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1371/journal.pone.0342452", "effect": "not extracted", "endpoint": "not extracted", "id": "source_7", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Stem cell therapy for female stress urinary incontinence: Results, limitations and lessons learned from a pilot clinical study", "type": "source", "url": "https://doi.org/10.1371/journal.pone.0342452", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fimmu.2026.1789537", "effect": "not extracted", "endpoint": "not extracted", "id": "source_8", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics", "type": "source", "url": "https://doi.org/10.3389/fimmu.2026.1789537", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.4252/wjsc.v17.i5.101675", "effect": "not extracted", "endpoint": "not extracted", "id": "source_9", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study", "type": "source", "url": "https://doi.org/10.4252/wjsc.v17.i5.101675", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13287-023-03390-9", "effect": "not extracted", "endpoint": "not extracted", "id": "source_10", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)", "type": "source", "url": "https://doi.org/10.1186/s13287-023-03390-9", "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1177/1098612X251385852", "effect": "not extracted", "endpoint": "not extracted", "id": "source_11", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Clinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis", "type": "source", "url": "https://doi.org/10.1177/1098612X251385852", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13287-023-03545-8", "effect": "not extracted", "endpoint": "not extracted", "id": "source_12", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Autologous mesenchymal stromal cells embedded with Tissucol Duo ® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up", "type": "source", "url": "https://doi.org/10.1186/s13287-023-03545-8", "year": 2023}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.3389/fphar.2024.1511525", "effect": "not extracted", "endpoint": "not extracted", "id": "source_13", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Protective effects and possible mechanisms of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles against kidney fibrosis in animal models: a systematic review and meta-analysis", "type": "source", "url": "https://doi.org/10.3389/fphar.2024.1511525", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s13287-023-03531-0", "effect": "not extracted", "endpoint": "not extracted", "id": "source_14", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of allogeneic umbilical cord-derived mesenchymal stem cells for the treatment of complex perianal fistula in Crohn’s disease: a pilot study", "type": "source", "url": "https://doi.org/10.1186/s13287-023-03531-0", "year": 2023}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1177/09636897261457229", "effect": "not extracted", "endpoint": "not extracted", "id": "source_15", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy", "type": "source", "url": "https://doi.org/10.1177/09636897261457229", "year": 2026}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/sctm.21-0021", "effect": "not extracted", "endpoint": "not extracted", "id": "source_16", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent stem cell‐derived mesenchymal stem cells", "type": "source", "url": "https://doi.org/10.1002/sctm.21-0021", "year": 2021}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_17", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_18", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_19", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_20", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.", "type": "source", "url": null, "year": null}, {"comparator": "not extracted", "directness": "citation", "doi": "10.1371/journal.pmed.0020124", "effect": "not extracted", "endpoint": "not extracted", "id": "source_21", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Ioannidis 2005", "type": "source", "url": "https://doi.org/10.1371/journal.pmed.0020124", "year": null}], "publication_id": "4a4ef105-6735-457c-a03e-c95da4a8e083", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 16, "included": 16, "included_or_retained": 16, "screened": 16, "wording": "16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "4a4ef105-6735-457c-a03e-c95da4a8e083",
  "researka_submission_id": "981aac7f-7cfa-497e-9dc9-ac4adf4aa402",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/4a4ef105-6735-457c-a03e-c95da4a8e083/sidecars/claim_graph.json"
}